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Abstract  
Transforming growth factor β1 (TGFβ)  is a tumor suppressor during the initial stage of 
tumorigenesis, but it can switch to a tumor promoter during neoplastic progression. Ionizing 
radiation (IR), both a carcinogen and a therapeutic agent, induces TGFβ activation in vivo. We 
now show that IR sensitizes human mammary epithelial cells (HMEC) to undergo TGFβ-
mediated epithelial to mesenchymal transition (EMT). Non-malignant HMEC (MCF10A, 
HMT3522 S1 and 184v) were irradiated with 2 Gy shortly after attachment in monolayer culture, 
or treated with a low concentration of TGFβ (0.4 ng/ml), or double-treated. All double-treated 
(IR+TGFβ) HMEC underwent a morphological shift from cuboidal to spindle-shaped. This 
phenotype was accompanied by decreased expression of epithelial markers E-cadherin, β-catenin 
and ZO-1, remodeling of the actin cytoskeleton, and increased expression of mesenchymal 
markers N-cadherin, fibronectin and vimentin. Furthermore, double-treatment increased cell 
motility, promoted invasion and disrupted acinar morphogenesis of cells subsequently plated in 
Matrigel. Neither radiation nor TGFβ alone elicited EMT, even though IR increased chronic 
TGFβ signaling and activity. Gene expression profiling revealed that double treated cells exhibit 
a specific 10-gene signature associated with Erk/MAPK signaling. We hypothesized that IR-
induced MAPK activation primes non-malignant HMEC to undergo TGFβ-mediated EMT.  
Consistent with this, Erk phosphorylation were transiently induced by irradiation, persisted in 
irradiated cells treated with TGFβ, and treatment with U0126, a Mek inhibitor, blocked the EMT 
phenotype. Together, these data demonstrate that the interactions between radiation-induced 
signaling pathways elicit heritable phenotypes that could contribute to neoplastic progression.  
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Introduction 
An emerging concept in cancer biology is that carcinogens can compromise tissue 
integrity by eliciting altered phenotypes and tissue composition (reviewed in (1)). 
Intercellular and extracellular signals are critical to the suppression of neoplastic growth 
while disruption of cell–cell and cell-matrix interactions is implicated, if not required, for 
neoplastic progression. Indeed, reversion of the malignant phenotype by modulating 
extracellular signals suggests that cancer cells are susceptible to signals from the 
microenvironment (2).  
We have postulated that ionizing radiation (IR) alters cell phenotypes, that in turn 
contribute, directly or indirectly, to carcinogenesis (3). IR activates multiple signaling 
pathways depending on the cell type, radiation dose and cell status (reviewed in (4)). IR 
also affects the activity or abundance of proteases, growth factors, cytokines, and 
adhesion proteins that are involved in tissue remodeling (reviewed in (5)). We have 
shown that transforming growth factor β1 (TGFβ) is activated following IR, and that it in 
turn mediates cellular and tissue radiation responses (6, 7). Although TGFβ is considered 
to be a potent tumor suppressor during the initial stage of tumorigenesis, principally 
through its ability to cause growth arrest and apoptosis, numerous reports show that 
TGFβ can switch to tumor promoter during neoplastic progression (reviewed in (8)). We 
have shown that the progeny of irradiated non-malignant human mammary epithelial 
cells (HMEC) cultured with TGFβ exhibit compromised morphogenesis, polarity and 
growth control when cultured in reconstituted basement membrane (9).  
Some epithelial tumors, particularly those that overexpress TGFβ (10), exhibit 
mesenchymal characteristics and are more aggressive. Several lines of evidence have led 
researchers to link this morphological shift during carcinogenesis to the physiological 
process of epithelial to mesenchymal transition (EMT). EMT is characterized by loss of 
epithelial cell polarity, loss of cell-cell contacts, acquisition of mesenchymal markers and 
phenotypic traits that include increased cell motility (reviewed in (11)). Although the 
clinical relevance of EMT in late-stage tumor progression is controversial, it is generally 
agreed that EMT can occur during cancer progression (11). Approximately 18% of breast 
cancers exhibit evidence of EMT (12). EMT has recently been reported during tumor 
recurrence after therapy (13). TGFβ has been particularly targeted as a mediator of EMT 
during neoplastic progression, but analysis of normal epithelial and cancer cell lines 
showed that TGFβ alone rarely induces EMT by (14).   
In the present studies, we found that a single exposure to IR sensitizes HMEC to undergo 
TGFβ-mediated EMT and exhibit all the classic hallmarks of EMT. Neither irradiation 
nor TGFβ alone was sufficient to elicit EMT even though TGFβ activity is elevated in 
irradiated cells. Gene expression profiling revealed a specific signature in double-treated 
cells associated with MAPK signaling. As previously reported, IR induces transient 
activation of the MAPK pathway, but exposure to low concentrations of TGFβ maintains 
this pathway activity, which is required for maintenance of EMT. We postulate that the 
pathway signaling interactions between radiation-induced MAPK and TGFβ elicit the 
heritable EMT phenotype.   
Materials and Methods 
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Cell culture: HMEC were cultured in serum free medium as previously described for 
HMT-3522 S1 (S1; passages 55-60) (15), MCF10A (ATCC, Manassas,VA), 184 HMEC 
(184v; passage 7-10) (16) and HMT-3522-S2 (S2) (17). Recombinant human TGFβ (0.4 
ng/ml) was added at the time of plating or of irradiation. HMEC were irradiated 4-5h (S1, 
MCF10A and S2) or 10-14h (184v HMEC) post plating using either 160 KV X-ray or 
60Co γ-radiation with a total dose of 2Gy. Control plates were sham irradiated. In some 
experiments, medium was supplemented with 10µg/ml TGFβ pan-specific neutralizing 
antibody (R&D Systems, Minneapolis, MN) or with an equivalent concentration of non-
specific mouse IgG. When noted, some cultures were treated with 10µm U0126 (Cell 
Signaling, Beverly, MA) or DMSO. 
Reagents: Antibodies to phosphorylated Erk1/2 (Thr202/Tyr204), phosphorylated MEK 
(Ser217/221), Erk1/2 and Mek1/2 were from Cell Signaling. Phalloidin was from 
Molecular Probes (Eugene, OR). E-cadherin, β-catenin and N-cadherin antibodies were 
purchased from BD Biosciences (San Jose, CA) and vimentin-clone VIM 13.2, β-actin 
and fibronectin antibodies were from Sigma (St. Louis, MO). ZO-1 antibody was 
obtained from Zymed (South San Francisco, CA). SMAD 2/3 antibody was purchased 
from Santa Cruz Biotechnology (Santa Cruz, CA). Recombinant TGFβ and TGFβ pan-
specific neutralizing antibody were obtained from R&D Systems. 
 
Immunofluorescence: Cells grown on LabTek 8-well chamber slides; fixed with 80% 
methanol for 10 min (N-cadherin, ZO-1) or methanol:acetone (vimentin, β-catenin) or 
4% paraformaldehyde (fibronectin, SMAD3, phalloidin) followed by treatment with 
0.1% Triton (N-cadherin, SMAD3) for 10 min. For E-cadherin staining cells were either 
fixed with 80% methanol or extracted with CSK buffer (15), followed by 4% 
paraformaldehyde fixation. Nuclei were counterstained with DAPI (4',6-Diamidino-2-
Phenylindole) using 0.5 ng/ml.  
 
TGFβ Bioassay: Mink lung cells transfected with the promoter of plasminogen activator 
inhibitor linked to a luciferase reporter (PAI-L) were used to analyze TGFβ in the 
conditioned media as previously reported (18). 
Protein analysis: Cells were lysed as previously described (15) or a in buffer containing 
50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.5 mM MgCl2, 0.2 mM EGTA, 1% Triton X-
100, protease inhibitor mixture (20 µl/ml; Sigma), 1 mM Pefabloc and 50mM glycerol-2-
phosphate (Sigma) or phosphatase inhibitor cocktail set II (Calbiochem, San Diego, CA). 
Extraction and immunoprecipitation of soluble and insoluble pools of E-cadherin was 
done as previously described (19). Proteins were separated on 4-15% SDS-PAGE gels 
and transferred to Immobilon-P (Millipore, Billerica, MA) or nitrocellulose (Amersham 
Lifescience); and probed with indicated primary antibodies. In some instances, detection 
was accomplished using chemiluminescence of secondary antibodies labeled with 
horseradish peroxidase followed by densitometry analysis of films. Alternatively, 
detection was performed using the Odyssey system (LI-COR, Lincoln, NE) as previously 
described (20). Target proteins were normalized to β-actin for loading.  
Motility and invasion assays: Confluent HMT3522 S1 or MCF10A cultures were grown 
in medium containing EGF. The cultures were scratched with a pipette tip and washed to 
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remove detached cells. The invasion assay was performed as previously described (21). 
The number of invading cells was the average of 3 wells from 2 duplicate experiments. 
RNA purification: Cells were washed with PBS; denatured in Trizol; scrapped and 
subjected to chloroform extraction. After centrifugation, the upper phase was precipitated 
with an equal volume of isopropanol. RNA precipitates were resuspended in RNase free 
water and further purified on RNeasy columns (Qiagen, Germany). RNA quality was 
assessed on an Agilent Bio-Analyzer. The dataset analyzed by microarray included 
biological duplicates for each treatment in two independent experiments and three sham-
treated samples.  
Microarray processing and analysis: Cy3/Cy5-labeled cDNAs were generated from RNA 
and hybridized to HG-U133A chips (Affymetrix Inc.,) at the Lawrence Berkeley National 
Laboratory HTArray Core Facility (http://hta.lbl.gov). Samples were analyzed and 
clustered with the (UNO) One Color GenetrafficTM software version 3.2-12 (Iobion 
Informatics LLC, Stratagene, La Jolla, CA). Genes whose expression was specifically 
altered by treatment were defined as those in which Cy5/Cy3 ratio was more than 1.75 
fold (|mean log2ratio|>0.8) from baseline in at least three out of the four treated samples 
compared to the three sham samples. Significance analysis tests (p<0.05) were performed 
using Excel between sham samples and either IR, TGFβ or TGFβ+IR samples. 
Real-time polymerase chain reaction (PCR): Total RNAs were pre-treated with 
amplification grade DNAse I (Invitrogen, Carlsbad, CA) then primed with random 
hexamers to generate cDNAs using a SuperscriptTM III first-strand synthesis kit according 
to the manufacturer’s intructions (Invitrogen). 1µl of non diluted cDNAs were then 
amplified with Lightcycler FastStart DNA master SYBR Green I (Roche Applied 
Science, Mannheim, Germany) using a Light Cycler (Roche Applied Science, Mannheim, 
Germany). TCF8, FGF2 and CDH1 specific primers optimized for SYBR Green real-
time PCR were purchased from SuperArray Bioscience Corporation (Frederick, MD).   
Image acquisition, processing and analysis: Imaging was done as previously described 
(20). Colony segmentation from phase images was done using live wire tool from 
MIPAV (22). Area and shape factors were calculated using Matlab (MathWorks Inc, 
Natick, MA) and DIPimage (image processing toolbox for Matlab, Delft University of 
Technology, The Netherlands).  
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Results 
The progeny of irradiated HMEC undergo EMT in response to TGFβ  
We previously reported that E-cadherin immunofluorescence significantly decreased in 
double-treated HMT3522 S1 cultured in Matrigel compared to control or single-treated 
cells and failed to establish acinar morphology typical of HMEC (9). EMT is one means 
of disrupting morphogenesis, e.g. during wound healing. To examine the possibility that 
EMT underlies the response to radiation and TGFβ, we compared the epithelial 
characteristics of HMEC in traditional monolayer culture. HMEC were irradiated with 2 
Gy shortly after attachment, or treated with low concentrations of TGFβ (400 pg/ml), or 
double-treated, and cultured to approximately 80% confluence. As observed previously, 
E-cadherin and β-catenin immunolocalization in monolayer HMEC was significantly 
reduced in double-treated cells (Figure 1A). The function of an epithelium as a barrier 
requires the establishment of tight junctions, evident by lateral, apical localization of ZO-
1. ZO-1 immunofluorescence showed distinct punctate localization at cell borders of 
control and irradiated cells. TGFβ treatment somewhat altered ZO-1 staining, such that it 
appeared as a coarser, punctate-like pattern at the cell boundaries (Figure 1A). However, 
ZO-1 staining completely disappeared in double-treated cells.  
Notably, double treatment resulted in spindle shaped, elongated cells, a phenotype which 
was examined by phalloidin staining of actin. Actin localized mainly at cell-cell borders 
of control and irradiated HMEC with very few stress fibers. TGFβ alone elicited a mild 
change in actin organization. Double-treated cells displayed dramatic actin reorganization 
consisting of longitudinal stress fibers, characteristic of fibroblasts (Figure 1A).  
In light of the loss of epithelial markers in irradiated HMEC cultured with TGFβ, we 
investigated whether there was a concomitant gain of mesenchymal markers, fibronectin, 
vimentin and N-cadherin (Figure 1B). Immunofluorescence analysis of the double-treated 
group revealed increased fibronectin deposition compared to sham and single-treated 
cells. Accumulated fibronectin was arrayed perpendicular to the cell edge and in 
randomly oriented networks. The intermediate filament protein vimentin dramatically 
increased following double treatment. Consistent with the shift to an elongated 
morphology, vimentin filaments were organized in a longitudinal meshwork. N-cadherin 
is normally present mainly in neuronal and muscle tissues, but is aberrantly expressed in 
epithelial tumors where it has been proposed to promote migration and invasiveness of 
carcinoma cells (23). N-cadherin immunofluorescence was dramatic increased following 
double treatment in a pattern reciprocal to E-cadherin loss.  
Loss of epithelial markers and gain of mesenchymal markers in double-treated cells was 
accompanied by epithelial to mesenchymal cell shape change. Phase microscopy 
HMT3522 S1, MCF10A and 184v HMEC (Figure 1C) showed that untreated HMEC and 
irradiated cells displayed typical cuboidal appearance of epithelial cells. TGFβ elicited a 
modest shape change, particularly in 184v HMEC. In contrast, the morphology of all 
three HMEC following double-treatment shifted to spindle-shaped. The morphological 
response was observed even when TGFβ was added 48h post-IR, and was not reversible 
upon removal of TGFβ from the culture media for 48h (data not shown). Taken together, 
the concomitant increased expression of mesenchymal markers, loss of epithelial markers 
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and morphological response of the progeny of irradiated HMEC to TGFβ suggest that 
cells have undergone EMT. 
TGFβ alters the cytoskeletal associated E-cadherin/β-catenin complexes in 
irradiated HMEC 
Although E-cadherin immunofluorescence was significantly reduced only in double-
treated cells (Figure 1A), western blot analysis of total E-cadherin protein expression 
levels were comparable in TGFβ-treated and double-treated groups (Figure 2A). β-
catenin protein levels followed the same pattern. This observation suggested that 
immunofluorescence was a function of protein localization, rather than abundance. In 
epithelial cells, E-cadherin and β-catenin are associated with the cytoskeleton at 
intercellular junctions that are resistant to detergent extraction (24). We tested whether 
the difference between immunofluorescence and immunoblotting was due to solubility by 
using differential detergent extraction followed by E-cadherin immunoprecipitation. 
Although TGFβ reduced the soluble pool of E-cadherin regardless of irradiation, the 
insoluble, cytoskeletal associated E-cadherin was significantly decreased only in double-
treated cells (Figure 2B). The distribution of β-catenin was similarly affected. Thus, 
TGFβ alters the cytoskeletal associated E-cadherin/β-catenin complexes only in 
irradiated HMEC. 
Functional consequence of the response of irradiated HMEC to TGFβ 
During physiological processes and in cancer, EMT is often accompanied by acquisition 
of cell motility and invasiveness (11). We analyzed the migratory properties of double-
treated HMEC using a monolayer scratch assay and time-lapse videomicroscopy (Figure 
3A). Control or irradiated cells moved as a sheet evidenced by a smooth edge and failed 
to fill the gap during the 40h observation period. Consistent with their intermediate 
cytoskeletal and cell-cell adhesion phenotype, TGFβ-treated HMEC began to close the 
wound after 20h, but the cells still maintained sheet formation and by 40h had not closed 
the gap. In contrast, irradiated HMEC cultured with TGFβ moved as single, spindle-
shaped cells and closed the gap by 40h by forming multicellular bridges of spindle 
shaped cells between the two areas.  Thus the tissue-specific requirement for epithelia to 
maintain cell interactions as a sheet of cohesive cells is disrupted when irradiated HMEC 
are exposed to TGFβ, which leads to independent single cell migration characteristic of 
mesenchymal cells.   
The above observations led us to further investigate the invasive properties of HMEC by 
invasion assay through a membrane coated with Matrigel, a basement membrane type 
matrix. HMT 3522 S1 did not invade in this assay under any condition. Therefore we 
used HMT 3522 S2, which are derived from further propagation of HMT 3522 S1 in 
EGF-free media (21). Cells were cultured as described above, then trypsinized and plated 
into the Boyden chamber assay in standard media. Few control HMT 3522 S2 cells were 
able to invade. The progeny of irradiated cells demonstrated greater invasion than 
treatment with TGFβ alone when compared to the control. In contrast, irradiation of S2 
cells and subsequent culture in the presence of TGFβ increased the number of invading 
cells more than 100-fold compared to sham (Figure 3B). 
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There is ongoing discussion in the literature as to what criteria define true EMT in vitro 
and how to distinguish the EMT phenotype from a 'scattering' phenotype (11). Both 
phenotypes exhibit disruption of cell junctions, fibroblast-type morphology, and 
enhanced motility. However, it has been suggested that they can be distinguished by 
reversibility since the EMT phenotype, but not the scattering phenotype, persists after 
withdrawal of the stimulus (11). As mentioned above, TGFβ withdrawal did not reverse 
the morphological shift, consistent with EMT. Since the progeny of irradiated HMEC 
cultured with TGFβ exhibit disrupted morphogenesis in Matrigel (9), we used 
morphogenesis as a stringent test of persistence. Single and double-treated HMEC cells 
were trypsinized and replated in Matrigel for analysis of acinar morphogenesis without 
further TGFβ stimulation. Replated double-treated cells formed larger colonies than 
control or single treated cells, which was measured by increased size and irregularity of 
colony shape (Figure 3C). We concluded that the phenotype elicited by IR and TGFβ 
resulting in dysplastic morphogenesis (i.e. 3D growth deregulation and disorganization) 
and the persistence of these morphological alterations in the absence of additional TGFβ 
is further evidence of EMT.  
 
Irradiated HMEC produce active TGFβ  
Latent TGFβ is activated in the irradiated mouse mammary gland in vivo (6), which 
could increase the susceptibility of irradiated cells to undergo TGFβ mediated EMT by 
decreasing a threshold response. Nuclear translocation of receptor phosphorylated 
SMAD2 or 3 (R-SMAD) results from liganded TGFβ receptor (8). Immunofluorescence 
analysis demonstrated that R-SMAD nuclear localization increased by 30% in irradiated 
HMEC 6 days after irradiation compared to control cells (Figure 4A). These data suggest 
that IR elicits persistent TGFβ signaling. To determine whether IR increased TGFβ 
production or activation, we analyzed the conditioned medium (CM) from irradiated cells 
using a TGFβ bioassay (18). Bioassay of irradiated and control HMEC CM indicated 
similar levels of latent TGFβ. Active TGFβ, however, was undetectable in either CM 
(data not shown). Since the sensitivity of detection in CM for the bioassay is 
approximately 0.2 ng/ml, we reasoned that low levels of TGFβ could be functional, 
although undetectable by bioassay. If so, then the CM should give rise to a similar 
phenotype in unirradiated HMEC seen in response to addition of exogenous TGFβ. To 
investigate this hypothesis, we fed non-irradiated HMEC with 50% CM from either 
irradiated or non-irradiated HMEC cultures. CM from irradiated cells caused a significant 
decrease in E-cadherin protein levels when compared to cells treated with CM from non-
irradiated cells. This response was reversed by adding TGFβ neutralizing antibody to the 
cells grown in the presence of IR-treated CM (Figure 4B). To confirm that this biological 
activity produced by irradiated cells was indeed TGFβ, irradiated cells were grown in the 
absence or presence of TGFβ neutralizing antibody. When irradiated HMEC were grown 
in the presence of TGFβ neutralizing antibody there was a significant reversal of the 
decrease in E-cadherin protein abundance compared to cells grown with control IgG 
control antibody (Figure 4C).  
Based on the above data, we estimated that irradiated cultures produce approximately 100 
pg/ml of active TGFβ. We then tested whether EMT was a function of the additive effect 
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of exogenous (400 pg/ml) and endogenous TGFβ (approximately 100 pg/ml) by treating 
HMEC with graded concentrations of TGFβ. However, MCF10A treated with up to 1200 
pg/ml TGFβ did not undergo EMT (data not shown). Although IR induced TGFβ activity 
in cultured HMEC, as it did in the mouse mammary gland (6), it was insufficient to 
disrupt HMEC acinar morphogenesis as shown in our previous study (9). Moreover, the 
progeny of irradiated HMT 3522 S1, MCF10A and 184v HMEC exhibited a modest 
response in terms of epithelial morphology, E-cadherin expression or invasion. Thus, 
chronic TGFβ activation by irradiated HMEC is insufficient to drive the EMT phenotype.   
 
Genetic programs underlying EMT in double-treated HMEC  
In order to comprehensively describe the altered epithelial cell phenotype following 
double treatment, we compared transcript expression levels in sham, IR-, TGFβ- and 
double-treated HMEC. The expression profile of the progeny of irradiated HMEC was 
similar to control HMEC. 43 genes were differentially expressed by TGFβ-treated 
HMEC that included 28 up-regulated genes and 15 down-regulated genes with a >1.75-
fold change in expression compared to sham samples (Supplementary Table). We 
identified 10 genes that constituted the double-treatment signature. Expression was 
significantly increased for five genes and decreased for the five other genes after double 
treatment compared to TGFβ alone.   
The five significantly up-regulated genes in double-treated samples were the growth 
factor FGF2/bFGF, the serine/cysteine proteinase inhibitor, SERPINA1, the interleukin 1 
receptor-like protein, IL1RL1, the transcription factor TCF8/ZEB-1 and the zinc 
transporter SLC39A8 (Figure 5A and B). The five down-regulated genes in double-
treated HMEC were the Wnt pathway transcription repressor secreted frizzle related 
protein 1 (SFRP1), the cystein-rich protein, CRIP2, the aldo-keto reductase, AKR1C2, 
the cadherin EGF LAG seven-pass G-type receptor 2(CELSR2), and the aminopeptidase 
O, C9orf3.  Although transcript levels of five of these ten genes (SERPINA1, SLC39A8, 
CRIP2, AKR1C2 and CELSR2) were higher in TGFβ-treated samples than in sham 
samples, they were below the 1.75-fold cut off used to define TGFβ-responsive genes. 
Changes in gene expression in double-treated HMEC were validated for TCF8 and FGF2, 
by real-time RT-PCR (Figure 5B). For comparison, real-time RT-PCR of E-cadherin 
(CDH1) was decreased in both TGFβ and double treated cells, consistent with the protein 
levels shown in Figure 2A. 
The EMT signature genes have roles in cell-matrix interactions, cell motility/invasion, 
inflammation and disruption of adherens junctions. The products of TCF8/ZEB1 and 
FGF2 have been described to repress E-cadherin transcription and to promote EMT (25, 
26). Some of the TGFβ -responsive and EMT-associated signatures genes identified here 
have been previously described (27, 28). An extensive bibliography search showed that 5 
of the 10 EMT signature genes are directly or indirectly associated with the Erk/MAPK 
pathway, suggesting a specific functional role of Erk/MAPK activation in inducing EMT 
upon double-treatment. Several reports suggest that an independent stimulus must 
synergistically proceed or at least accompany the induction of EMT. The multiple 
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downstream effectors of Ras, such as MAPK, may be a requirement to induce a pre-
malignant state and endow epithelial cells with an increased rate of proliferation (29). 
 
Persistent activation of Erk/MAPK in double-treated HMEC 
Consequently, we examined the possible involvement of the Erk/MAPK signaling 
cascade in the mediation of TGFβ-induced EMT in irradiated HMEC by determining the 
activation of Erk1/2 and upstream activators, Mek1/2. The total amounts of Erk or Mek 
were similar following all treatments. Phosphorylated-Erk1/2 was modestly induced by 
TGFβ but was significantly increased in irradiated HMEC treated with TGFβ (Figure 6A, 
top panel). Consistent with this, Mek1/2 activation, as indicated by phosphorylation, was 
also increased upon double treatment.  
There is a significant body of literature that suggests that Erk activation is required to 
initiate the EMT program (30, 31). IR can induce a rapid, ligand-independent activation 
of Erk/MAPK in cancer cells (32). To investigate whether activation of Erk1/2 by IR or 
TGFβ versus double treatment was indeed instrumental in driving EMT, we monitored 
Mek/Erk activation at early time points (4-48h post IR). At 8h, Erk1/2 phosphorylation 
was significantly induced by IR when compared to TGFβ or double-treatment. From 12-
24h, MAPK pathway activation increased following IR or TGFβ or double treatment 
compared to controls. However, at 48h post-IR, double-treated cells exhibited greater Erk 
activation compared to control and to single-treated HMEC (Figure 6, bottom panel).  
To determine if persistent Erk activation was required for the EMT phenotype in double-
treated HMEC, we used U0126, a specific Mek small molecule inhibitor. Treatment with 
U0126 dramatically decreased Erk activation in HMEC (Figure 6B). Treatment with 
U0126 also restored E-cadherin and cytoskeletal rearrangement (Figure 6C) and reduced 
cell migration in the wound closure assay (Figure 6D). These data suggest that IR and 
TGFβ collaborate to increase Erk activation, which is necessary for establishment and 
maintenance of EMT (7 days). We propose that transient IR-induced Erk activation is 
sustained in the presence of additional TGFβ, and that this event predisposes non-
malignant HMEC to undergo TGFβ-mediated EMT.   
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Discussion  
Here we report that the progeny of irradiated HMEC are dramatically sensitized to 
undergo TGFβ-induced EMT. IR and TGFβ cooperated to induce a phenotypic transition 
that occurred in the progeny of cells irradiated once and persisted even in the absence of 
TGFβ. This resulted in increased motility, enhanced invasion, disrupted epithelial 
morphogenesis, and was accompanied by a distinct pattern of gene expression.   
TGFβ has long been considered as both a positive and a negative effector of mammary 
tumorigenesis, acting early as a tumor suppressor but later as a stimulator of tumor 
invasion (8). Overexpression of constitutively active TGFβ can induce EMT during 
tumor progression in vivo (33) and the overexpression of TGFβ has been associated with 
poor prognosis of many human cancers (8). The phenotypes of breast cancer 
micrometastases in lymph nodes and the bone marrow have been interpreted as evidence 
that EMT occurs in primary tumors (34). However in vivo verification of EMT has been 
controversial, perhaps due to the transient and reversible nature of the process and to the 
lack of analytical tools that distinguish carcinoma cells undergoing EMT from 
neighboring stromal fibroblasts.   
In vitro studies of EMT were originally described in cells of murine origin, frequently 
containing ras mutations. It has been reported in a very limited number of human cell 
lines, and very rarely in non-malignant cell lines (35, 36). The in vitro studies in which 
TGFβ alone is capable of inducing EMT have either been performed in serum containing 
medium, which provides various growth factors commonly associated with wounding, 
including TGFβ, FGF and EGF, and/or using high TGFβ concentrations (2.5-10ng/ml) 
(36, 37). Expression profiling of genetic program underlying EMT of HaCat 
keratinocytes stimulated with TGFβ to undergo EMT identified 80 EMT-related targets 
(27). Our expression profiling study distinguishes between genes regulated by 
TGFβ without concomitant EMT in non-malignant HMEC and genes that are 
differentially expressed under conditions resulting in EMT.  
We identified 10 genes specifically associated with EMT, five of which were not induced 
at all by TGFβ alone. Transcriptional repression of E-cadherin, could be mediated by the 
transcription factor TCF8/ZEB1 (25). FGF2, whose transcript expression is significantly 
increased upon double treatment in this EMT model, has also been linked to E-cadherin 
repression and EMT (25, 26). Low E-cadherin immunoreactivity in breast cancer is 
associated with poor prognosis (38), whereas restoration of E-cadherin reverts the 
invasive phenotype of cancer cells (39). Irradiated HMEC redistribute E-cadherin from 
an insoluble to a soluble pool when cultured with TGFβ, which is accompanied by a 
significant increase in N-cadherin. The cadherin switch from E- to N-cadherin frequently 
accompanies pronounced tissue reorganization in normal and pathological conditions 
(40). Studies on cancer cell lines indicate that N-cadherin is linked to a more malignant 
and invasive behavior (23). Consistent with this, double-treated HMEC were significantly 
more motile. Although double-treated HMT-3522 S1 cells were not invasive, double-
treatment induced invasive behavior in HMT-3522 S2 cells, which are an EGF-
independent strain of the HMT-3522 progression series.  
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Neither chronic TGFβ signaling induced by irradiation nor supplementation with low 
TGFβ concentrations was sufficient to induce the EMT phenotype in any of the three 
HMEC that were examined in our studies. EMT occurred only in irradiated HMEC in the 
presence of TGFβ, even when TGFβ was added 2 days post-IR. This suggested that a IR-
induced event was a prerequisite for TGFβ-mediated EMT that was sustained for 48h. IR 
initially induces a transient activation of Erk/MAPK via a ligand-independent mechanism 
(32). Although the involvement of Erk signaling in TGFβ–induced EMT is controversial 
(41), many studies have shown a requirement for overexpression/mutational activation of 
elements of the Ras/Raf/Erk pathway for TGFβ–mediated EMT (41-43). Furthermore, 
the importance of enhanced Erk activation in induction of EMT is also supported by 
studies in which Erk activity induced by Ras/TGFβ (41), EGF/TGFβ (31), HGF/ErB2 
(44) and Akt (45), was found to be critically involved in EMT. Our data suggest a model 
in which IR-induced Erk/MAPK signaling is sustained by TGFβ, is required for 
establishing and maintaining EMT, and is essential for the functional response, i.e. 
enhanced migration. 
Cancer radiotherapy is primarily limited in many organs by the risk of developing 
fibrosis (46). Neilson and colleagues demonstrated EMT as a significant source of 
fibrosis in a kidney ligation model (47). An interesting implication from our study is that 
normal epithelia may undergo EMT in response to irradiation and TGFβ, which could 
contribute to fibrosis following radiotherapy. If so, this would lend further credence to 
the potential application of TGFβ inhibitors in radiotherapy.  
Based on studies in mouse mammary gland, we proposed that the action of radiation as a 
carcinogen is augmented by its ability to modulate signaling from the microenvironment 
(48). Tumorigenesis is increased 4-fold when unirradiated preneoplastic mammary 
epithelial cells are transplanted to the mammary stroma of a host irradiated with 4 Gy (3). 
IR induces abundant TGFβ activation (6). Our current and earlier studies (9) have shown 
that irradiated non-malignant HMEC undergo EMT only if they are exposed to additional 
TGFβ, as might be derived from the stroma in intact tissues. If moderate radiation doses 
can prime preneoplastic cells to undergo EMT, it could accelerate cancer progression. 
Interestingly, a recent study shows that conventional renal cell carcinomas of the 
Ukrainian patients living in the radio-contaminated areas exhibited significantly higher 
levels of TGFβ expression compared to similar tumors in populations in uncontaminated 
areas (49). These tumors were characterized by decreased or abnormal distribution of 
fibronectin, laminin, and E-cadherin/βcatenin, suggesting that chronic low level radiation 
exposure in humans might indeed shift tumors towards a mesenchymal phenotype. 
Nonetheless there is little evidence to support these events occurring in normal epithelia 
in vivo after moderate doses. Furthermore, additional studies from our laboratory indicate 
that TGFβ is instrumental in mounting a DNA damage response (7, 20), and in inducing 
apoptosis of genomically unstable cells (Barcellos-Hoff, M.H. and Maxwell, C.A. 
unpublished observations). The complexity of radiation effects mediated by TGFβ will 
require further study to determine whether it plays a proximal role in suppressing or 
promoting radiogenic carcinogenesis.  
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 Figure Legends  
Figure 1 
Loss of epithelial and gain of mesenchymal markers in irradiated HMEC in 
response to TGFβ 
(A) Immunolocalization of cytoskeleton-associated E-cadherin, β-catenin, ZO-1, F-actin 
(detected with phalloidin) (B) fibronectin, vimentin and N-cadherin in sham (untreated), 
IR, TGFβ and double-treated (IR+TGFβ) HMT3522 S1 cells. All images were acquired 
at 40x magnification. (C) Phase images of sham, IR, TGFβ and IR+TGFβ treated 
HMT3522 S1 (day 10), MCF10A (day 10) and 184v HMEC (day 7). The images were 
acquired at 10x magnification. All images in (A), (B) and (C) are representative of three 
independent experiments. 
 
Figure 2 
TGFβ alters the cytoskeletal associated E-cadherin/β-catenin complexes in 
irradiated HMEC 
(A) Immunoblots and quantification of E-cadherin and β-catenin in total protein extracts 
from sham, IR, TGFβ or IR+ TGFβ HMT3522 S1 cultures. The graph represents 
quantification of E-cadherin protein abundance from nine independent experiments 
normalized to β-actin shown as mean±standard error. β-actin indicates equal protein 
loading. (B) Immunoblot of E-cadherin and β-catenin expression in E-cadherin 
immunoprecipitates from Triton soluble (S) and insoluble (I) protein extracts of 
HMT3522 S1 cells. (Student’s t-test, p ** <0.0001)  
 
Figure 3 
TGFβ induces an increase in motility and invasiveness in irradiated HMEC.   
(A) Wound closure assay in sham, IR, TGFβ and IR+ TGFβ treated HMT3522 S1 cells. 
Representative images captured with a 10x objective at the time of wounding (0h) and 
20h or 40h after wounding. All experiments were repeated at least 3 times, with similar 
results. (B) Quantification of transwell migration assay using HMT3522 S2 cells. Values 
represent mean±SE of total cell counts of each well from duplicate experiments. (C) 
Further propagation of MCF10A in 3D matrix without additional treatment. Sham, IR or 
TGFβ-treated or double-treated MCF10A were grown to 80-90% confluency, trypsinized 
and embedded in Matrigel as previously described (9). Phase images of acini embedded 
in Matrigel were captured using 10x magnification. Acini were identified using the live 
wire tool from MIPAV and batch processed by in-house measurement routines (see 
material and method for details). Three separate experiments with multiple independent 
samples were analyzed. Averages of acini areas were plotted against their average shape 
factor for each sample. The shape factor is defined as P2/(4.π.A) where P is the perimeter 
and A the area of the acinus. This value is equal to one for a perfect circle. A value 
greater than 1 is interpreted as the amount of deformation in comparison to a circle. 
Averages of acini areas were plotted against their average shape factor for each sample. 
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A p-value of 1.8E-5 was obtained between sham and double treatment. All other groups 
could not be distinguished from sham. The circles on the scatterplot delimit the double-
treated group compared to the other groups and indicates that double treatment leads to 
larger and more deformed acini. Statistical analysis of the 2D scatter plot between area 
and shape factor was performed by using multivariate analysis of variance (50).  
 
 Figure 4 
Persistent effect of IR predisposes HMEC to TGFβ-induced EMT  
(A) Immunolocalization and quantification of SMAD in sham and IR-treated  HMT3522 
S1 cultures at day 6 post plating. The graph represents quantification of nuclear SMAD 
positive cells from one of three experiments (mean± SD; sham n=5464 cells, IR n=4876 
cells). (B) Quantification of E-cadherin protein abundance from three independent 
experiments normalized to β-actin is shown as mean±SE. HMT3522S1 cells were grown 
for 10 days in the presence of 50% CM from control (sham-CM) or irradiated (IR-CM) 
cells in presence of TGFβ neutralizing antibody or non specific IgG. (C) E-cadherin 
protein abundance in sham and IR-treated cells treated with TGFβ neutralizing antibody 
(TGFβ−ΝΑb) or non specific IgG. Values are representative of 3 experiments normalized 
to β-actin shown as mean ± SE.  (Student’s t-test, p * <0.01; p ** <0.001; p *** <0.0001) 
 
Figure 5 
Gene expression profiles of double-treated HMEC. 
 (A) Microarray transcript profiling for 10 EMT signature genes (FGF2, SERPINA1, 
IL1RL1, TCF8, SLC39A8, SFRP1, CRIP2, AKR1C2, CELSR2 and C9orf3) in sham, IR-
treated, TGFβ-treated and double-treated MCF10A cells 8 days post-IR. Biological 
replicates are shown.  Although transcript levels of five of these ten genes (SERPINA1, 
SLC39A8, CRIP2, AKR1C2 and CELSR2) were significantly (<p, 0.05) higher in TGFβ-
treated samples than in sham samples, alterations changes were all below the 1.75-fold 
cut off used to define TGFβ-responsive genes. The graph represents significance analysis 
of alterations in transcript expression levels (±SE) for the 10 EMT signature genes 
including the experiment shown in panel A and a replicate independent experiment (1 
probe per gene except for FGF2 (2 probes) and SFRP1 (3 probes)), (B) Validation of 
microarray profiling for TCF8, FGF2 and CDH1 (E-cadherin) by real-time PCR. 
Increased TCF8 and FGF2 mRNA abundance is illustrated by a shift towards the left of 
the real time PCR curves in double-treated samples. CDH1 was decreased (right shifted 
curve) in TGFβ-treated and double-treated samples. (Student’s t-test, p * <0.05; p ** 
<0.001; p *** <0.0001). 
 
Figure 6 
Kinetics of MAPK signaling in HMEC as a function of IR and TGFβ treatment.  
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(A) Erk and Mek activation in sham, IR, TGFβ and IR+TGFβ treated 184v HMEC. 
Sham, IR, TGFβ and IR+TGFβ treated cells were lysed 7 days (top panel) or 4-48h 
(bottom panel) post-IR, and immunoblotted with the indicated antibodies. Graphs 
represent densitometric analysis of immunoblots of phosphorylated Erk and/or Mek 
normalized to respective total protein. Error bars represent ± S.E. (B) At 6 days post-IR 
184v HMEC were treated with DMSO or U0126 (10µM). 8h after treatment cells were 
lysed, and immunoblotted with the indicated antibodies. (C) Sham, IR, TGFβ and 
IR+TGFβ treated MCF10A cells (6 days post plating) were cultured in DMSO or U0126 
(10µM) for 30h, followed by staining for F-actin (detected with phalloidin) and E-
cadherin. Representative images of only IR+TGFβ treated cells are shown. E-cadherin 
and phalloidin images are representative of three and two independent experiments 
respectively. (D) Representative phase images of wound closure assay of sham, IR, 
TGFβ and IR+TGFβ in presence of DMSO or U0126 (10µM) at 0h and 14h. Images 
were acquired 14h after addition of DMSO or U0126. Phase images were captured using 
4x objective. Three independent experiments were done and the graphs represent 
percentage of wound closure (±SD) at 14h after treatment from one such experiment.  
 
Supplemental files 
Two lists of up-regulated and down-regulated genes upon TGFβ treatment are provided. 
As described in the Methods section, TGFβ responsive genes are defined as genes for 
which at least three out of the four biological samples tested show a change of at least 
1.75-fold compared to sham samples. In each list, genes are ranked from the most to the 
least responsive gene according to the averaged fold change in transcript level. The 
number of biological samples where the expression change is observed is indicated. 
 
 






